Clinical
RSSArticles
-
Where do pills fit in the family planning picture?
In national statistics, the pill continues to lead the pack, with 25.9% of contracepting women (9.7 million women) reporting its use. Female sterilization was listed by 25.1% (9.4 million women), followed by the male condom (15.3%, 5.8 million women) and long-acting reversible contraception (11.6%, 4.4 million women).
-
Should oral contraceptives move over the counter? Readers speak out
Most participants in the Contraceptive Technology Update Contraception Survey say they support moving oral contraceptives over the counter. Almost 50% say they would support OTC availability of progestin-only pills, while 32% say they would support similar availability of combined hormonal pills.
-
Focus on the contraceptive implant — Insert it in your family planning practice
About 30% of participants in the 2015 Contraceptive Technology Update Contraception Survey reported 25 or more implant insertions in the past year, with 14% saying they inserted 11 to 24 devices.
-
Survey profile
The 2015 Contraceptive Technology Update Contraception Survey monitors contraceptive trends and family planning issues among readers. Results were tallied and analyzed by AHC Media in Atlanta, which publishes CTU and dozens of other healthcare newsletters and sourcebooks and presents webinars and conferences.
-
Survey results show use of LARC continues to rise
About 46% of participants in the 2015 Contraceptive Technology Update Contraception Survey say they have seen “dramatically more” women choosing long-acting reversible contraceptive methods such as the intrauterine device and contraceptive implant in the last year.
-
Ceftazidime-avibactam — Formulary Considerations
Ceftazidime-avibactam is a new beta-lactam/beta-lactamase inhibitor combination approved for the treatment of complicated intra-abdominal infections in combination with metronidazole, and complicated urinary tract infections, including pyelonephritis in patients with limited alternative treatment options.
-
Idarucizumab Injection (Praxbind)
The FDA has approved the first reversal agent for a direct oral anticoagulant. Idarucizumab is a humanized monoclonal antibody fragment derived from an IgG1 isotype molecule. -
Optimal Beta-blocker Dose Post-MI
Beta-blocker therapy after acute myocardial infarction was retired as a hospital performance measure because its almost universal acceptance removed its discriminating value. However, it is well known that clinically used doses are significantly lower than those achieved in the randomized trials, establishing their mortality-reducing benefits.
-
Can We Safely Discharge Patients on the Weekend?
ABSTRACT & COMMENTARY: The link between weekend discharge and 30- and 90-day readmission rates.
-
Evaluation of Syncope
MONOGRAPH: Here's how to determine the appropriate treatment and disposition outcomes in the most time- and cost-effective manner.